Management of neonatal narcotic abstinence utilizing a phenobarbital loading dose method

Area of Science:

• Neonatal care
• Pharmacology
• Pediatric neurology

Background:

• Neonatal Abstinence Syndrome (NAS) is a significant concern in infants exposed to substances prenatally.
• Prenatal methadone exposure is a common cause of NAS, requiring effective treatment strategies.
• Phenobarbital is a potential therapeutic agent for managing NAS symptoms.

Purpose of the Study:

• To evaluate the efficacy of phenobarbital in treating NAS caused by prenatal methadone exposure.
• To establish optimal phenobarbital dosing and monitoring parameters for NAS management.
• To identify criteria for medication discontinuation and infant discharge.

Main Methods:

• A cohort of eighteen infants with NAS due to prenatal methadone exposure was studied.
• Phenobarbital was administered with an initial loading dose, followed by adjusted maintenance doses based on blood levels.
• A multifactorial abstinence scoring system was employed to monitor symptomatology and correlate with serum phenobarbital levels.

Main Results:

• Phenobarbital adequately controlled NAS symptoms in most infants.
• Serum phenobarbital levels of 20-30 mcg/ml were sufficient for symptom control.
• Tapering phenobarbital to 10-12 mcg/ml with minimal abstinence scores (≤8 for 72 hours) indicated readiness for discharge.

Conclusions:

• Phenobarbital is an effective treatment for neonatal abstinence syndrome secondary to prenatal methadone exposure.
• Therapeutic drug monitoring and a standardized scoring system facilitate optimized dosing and safe discontinuation of phenobarbital.
• This approach allows for timely and medication-free discharge of infants recovering from NAS.